Oncopeptides AB (publ) (STO:ONCO)

Market Cap	324.50M
Revenue (ttm)	31.65M
Net Income (ttm)	-284.61M
Shares Out	215.19M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	133,253
Average Volume	771,638
Open	1.520
Previous Close	1.500
Day's Range	1.462 - 1.546
52-Week Range	1.100 - 7.090
Beta	-0.45
RSI	46.93
Earnings Date	May 15, 2025

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 80
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.